genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of samples aids real-time decisionmaking, whether in clinical, public health or biothreat applications. GDR is developing a portfolio of assays for the Genedrive device. Its hepatitis C virus (HCV) and pathogen detection assays are already on the market, and products for tuberculosis (TB) and screening against adverse reactions to antibiotics are in development.
28 Oct 2019
Acceleration of news flow expected
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Acceleration of news flow expected
Genedrive Plc (GDR:LON) | 5.8 0 (-2.1%) | Mkt Cap: 8.23m
- Published:
28 Oct 2019 -
Author:
Martin Hall -
Pages:
16
genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of samples aids real-time decisionmaking, whether in clinical, public health or biothreat applications. GDR is developing a portfolio of assays for the Genedrive device. Its hepatitis C virus (HCV) and pathogen detection assays are already on the market, and products for tuberculosis (TB) and screening against adverse reactions to antibiotics are in development.